Related Experiment Videos
Inhibition of the signalling kinase JAK3 alleviates inflammation in monoarthritic rats
Byung-Hak Kim1, Myunghwan Kim, Chang-Hong Yin
1Department of Pediatrics, New York Medical College, Valhalla, New York, USA.
Background And Purpose:
Many cytokines associated with autoimmune disorders and inflammation have been shown to activate the signalling kinase JAK3, implying that JAK3 plays key roles in the pathogenesis of these diseases. Therefore, investigating the alterations of JAK3 activity and the efficacy of selective JAK3 antagonists in animal models of such disorders is essential to a better understanding of the biology of JAK3 and to assess the potential clinical benefits of JAK3 inhibitors.
Experimental Approach:
Through high-throughput cell-based screening using the NCI compound library, we identified NSC163088 (berberine chloride) as a novel inhibitor of JAK3. Specificity and efficacy of this compound were investigated in both cellular and animal models.
Key Results:
We show that berberine chloride has selectivity for JAK3 over other JAK kinase members, as well as over other oncogenic kinases such as Src, in various cellular assays. Biochemical and modelling studies strongly suggested that berberine chloride bound directly to the kinase domain of JAK3. Also phospho-JAK3 levels were significantly increased in the synovial tissues of rat joints with acute inflammation, and the treatment of these rats with berberine chloride decreased JAK3 phosphorylation and suppressed the inflammatory responses.
Conclusions And Implications:
The up-regulation of JAK3/STATs was closely correlated with acute arthritic inflammation and that inhibition of JAK3 activity by JAK3 antagonists, such as berberine chloride, alleviated the inflammation in vivo.
Insights
Berberine chloride selectively inhibits Janus kinase 3 (JAK3), a key player in autoimmune disorders. This JAK3 inhibitor reduced inflammation in animal models, showing potential for treating inflammatory diseases.
Area of Science:
- Immunology
- Molecular Biology
- Pharmacology
Background:
- Janus kinase 3 (JAK3) signaling is implicated in autoimmune disorders and inflammation.
- Understanding JAK3 activity and inhibitors is crucial for developing new treatments.
Purpose of the Study:
- To identify novel JAK3 inhibitors.
- To evaluate the efficacy of identified inhibitors in cellular and animal models of inflammation.
Main Methods:
- High-throughput screening of the NCI compound library identified NSC163088 (berberine chloride) as a JAK3 inhibitor.
- Specificity and efficacy were tested in cellular assays and animal models.
Main Results:
- Berberine chloride demonstrated selectivity for JAK3 over other kinases.
- Biochemical studies indicated direct binding of berberine chloride to the JAK3 kinase domain.
- In an inflamed rat joint model, berberine chloride treatment reduced JAK3 phosphorylation and suppressed inflammation.
Conclusions:
- JAK3/STATs signaling is upregulated in acute arthritis.
- Inhibiting JAK3 activity with berberine chloride alleviated inflammation in vivo, suggesting therapeutic potential.
